CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase

Affiliations

• ¹ Hematology Department, Hospital Universitario Salamanca, Salamanca, Spain.
• ² IBSAL, IBMCC-Cancer Research Center, University of Salamanca, Salamanca, Spain.
• ³ Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
• ⁴ Center of Molecular Biology and Gene Therapy, Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Medical Faculty, Masaryk University, Brno, Czech Republic.
• ⁵ Research Programon Biomedical Informatics, IMIM Hospital del Mar Medical Research Institute and Universitat Pompeu Fabra, Barcelona, Spain.
• ⁶ Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain.
• ⁷ Hematology Department, Hospital Clínico Universitario of Valladolid, Valladolid, Spain.
• ⁸ Hematology Department, Hospital Universitario Salamanca, Salamanca, Spain. [email protected].
• ⁹ IBSAL, IBMCC-Cancer Research Center, University of Salamanca, Salamanca, Spain. [email protected].
• ¹⁰ Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic. [email protected].
• ¹¹ Center of Molecular Biology and Gene Therapy, Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Medical Faculty, Masaryk University, Brno, Czech Republic. [email protected].